Actemra

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

Recent Entrants Invest Heavily in Promotion to Capture Share in Mature Market, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues,...

Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis

However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leadi...

Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis

The first Phase III study involving the use of Actemra in the treatment of rheumatoid arthritis has revealed that it is superior to conventional treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs to inhibit // joint destruction. It has also been found to provide symptomatic...

Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA

...he established TNFs (Enbrel, Humira, and Remicade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that actemra would be most likely to replace BMS's Orencia in their practices. LaunchTrends (TM) measure launch effectiveness of new products from FDA appr...

ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress

...f Phase III clinical studies highlight benefits of actemra as a treatment for rheumatoid arthritis - NUT... About ACTEMRA(R) (tocilizumab) actemra is the first humanized interleukin-6 (IL-6) recept...nd have reported meeting their primary endpoints. actemra is currently under review by the FDA in the United...

FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis

...ommittee, we are hopeful that the FDA will approve actemra for the treatment of RA and provide a new option t...nt program was designed to evaluate the effects of actemra on signs and symptoms of RA, physical function, pr...(TNF) therapy, and one monotherapy study comparing actemra to methotrexate, a current standard of care, was a...

Roches Arthritis Drug Successful in III Stage Trail

... Roche Holding AG says that arthritis drug actemra has proved successful in a phase III clinical study. actemra helps relieve symptoms of rheumatoid arthritis in...eeks with 498 patients with difficult-to-treat RA. actemra was given in combination with a standard treatment...

New Drug for Rheumatoid Arthritis Looks Promising.

...y. Drug maker Roche Holding AG will file the drug actemra for regulatory approval in Europe and the U.S. lat...ntrolled by Roche. Roche owns the rights to market actemra outside Japan. Two other drugs rituxima...d to disability. The new treatment option actemra in combination with traditional drugs achieved a s...

Actemra in Medical Technology

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

- By targeting interleukin-6 receptors, ACTEMRA provides significant benefits for patients when compared with existing therapies - NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced significant and rapid re...

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

... - Additional data reinforce long-term efficacy of actemra across a broad range of rheumatoid arthritis patie...ng with additional studies that support the use of actemra as a long-term treatment option for patients with ...30 percent and 47 percent of patients treated with actemra 4 mg/kg and 8 mg/kg, respectively, compared with 8...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

... - Fifth International Phase III actemra Study Meets its Primary Endpoints - NUTLEY, N...RA). The study also showed that patients receiving actemra experienced improved physical function, as measure...fth international Phase III study in the extensive actemra clinical development program to successfully meet ...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

...health care professionals prescribe and administer actemra correctly, and that patients understand the potent...animal model data, beyond what was included in the actemra BLA. Roche is performing the requested pre-clinica...s to confirm the published literature showing that actemra does not affect peri- and post-natal development, ...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

...mproved physical function in patients treated with actemra - NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year... "The LITHE study demonstrated that treatment with actemra inhibited structural joint damage, which is a majo...erosion and joint space narrowing, was lower among actemra (8 mg/kg and 4 mg/kg) plus methotrexate-treated pa...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

...ions, along with 13 other abstracts which evaluate actemra in patients with moderately to severely active RA,...studies further support the efficacy and safety of actemra as a potential new treatment option for managing t... The AMBITION study, which examined the effects of actemra (8 mg/kg) as monotherapy, showed that 70 percent o...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

... - Phase III monotherapy study shows actemra is first and only biologic to demonstrate statis... showed that significantly more patients receiving actemra achieved a 20 percent improvement in their signs a...r at week 24. In addition, nearly one-third of all actemra patients from both studies reached disease remissi...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

...e LITHE study is the fifth international Phase III actemra trial to successfully meet its primary endpoints i...that a greater proportion of patients treated with actemra (4 mg/kg or 8 mg/kg) plus methotrexate versus plac...ent of the patients were from the United States. actemra was generally well tolerated; the most common adve...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

...evere rheumatoid arthritis (RA). "The filing for actemra represents a significant milestone for Roche, and ...ombie, President and CEO, Hoffmann-La Roche Inc. actemra is the first humanized interleukin-6 (IL-6) recept...international Phase III studies which demonstrated actemra as monotherapy or in combination with disease modi...

Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms

...toms achieved with the unique inhibiting action of actemra that specifically targets interleukin-...the findings of this new TOWARD data which suggest actemra plus DMARDs demonstrates significant improvement i...rom both studies further establish the efficacy of actemra and confirm that inhibiting interleukin-6 (IL-6) r...

Actemra in Biological News

New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis

The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to achieve an adequate response to traditional disease modifying agents (DMARDs). Exciting new data from the TOWARD1...

Actemra in Biological Technology

Baseline Research Indicates High Interest in Centocor-Ortho Biotech's SIMPONI(R)

...of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in actemra compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a grea...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

... - Phase III data highlight the benefits of actemra for rheumatoid arthritis - NUTLEY, N.J., Oct. 20...ing results from the extensive multi-national actemra clinical development program, which included ...atients in 41 countries, including the U.S. About actemra (tocilizumab) ...

Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report

...ol-Myers Squibb); MabThera (rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab (Amgen); golimumab (Centocor/Schering-Plough/Essex); actemra (tocilizumab; Roche/Chugai); Cimzia (certolizumab; UCB); GA101 (anti-BR3-Fc/anti-BR3 MAb Biogen/Genentech); LymphoStat-B(R) (belimumab; Human Genome S...